Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

PD-1 Combinations Explored in RCC

July 18th 2014

Immunotherapy Combination Strategies in RCC

July 18th 2014

Sequencing Checkpoint Inhibitors in NSCLC

July 18th 2014

Optimizing Checkpoint Inhibition in NSCLC

July 18th 2014

Immune Checkpoint Inhibitors in NSCLC

July 18th 2014

Evolving Renal Cell Carcinoma Treatment Paradigm

July 18th 2014

Rini Explores PD-1 Inhibition in Renal Cell Carcinoma

July 18th 2014

Development of Checkpoint Inhibitors for GU Cancers

July 18th 2014

Checkpoint Inhibition in Renal Cell Carcinoma

July 18th 2014

Utility of PD-L1 as a Biomarker in Bladder Cancer

July 18th 2014

Evolving Role of PD-L1 as a Biomarker

July 18th 2014

PD-L1 Immunotherapy in Bladder Cancer

July 18th 2014

Targeted Immunotherapy in Cancer

July 18th 2014

Future Role of Immunotherapy in Cancer

July 18th 2014

PD-L1 Inhibition With MPDL3280A in Bladder Cancer

July 18th 2014

Adjuvant Ipilimumab in High-Risk Melanoma

July 18th 2014

Checkpoint Inhibitor Combination Strategies

July 18th 2014

Future Role of Checkpoint Inhibitors in Melanoma

July 18th 2014

Checkpoint Inhibitors in Metastatic Melanoma

July 18th 2014

Introduction: Immunotherapy Research Milestones

July 18th 2014